Why a “Top 10 Sales” analysis matters in 2025
Think of a Top 10 list as a compressed snapshot of how money moves in a market. When the same medicine ranks very differently across countries, it’s rarely because the clinical value changed—it’s because the system around the drug is different: who pays (payer mix), where it is dispensed (channel structure), and how prices and reimbursement are set (pricing, coverage, and controls).
That’s why 2025 is especially worth analyzing. Globally, metabolic disease—particularly GLP-1s—has shifted from a “growth segment” to the center of cash flow. In China, the outpatient (pharmacy) channel is becoming more prescription-driven, with higher-priced medicines increasingly moving outside hospitals. Korea, meanwhile, remains a market where outpatient prescription penetration in chronic diseases is a major driver of sales. These are structural changes that do not end in 2025; they are likely to carry directly into 2026 planning.
The U.S. top 10 drug sales “bestseller formula”: not “unusual” drugs, but large markets with long duration
In the United States, Top 10 revenue is typically driven less by novelty and more by scale and duration: drugs that can be used long-term in large indications—and that can be absorbed by the insurance system (commercial and public payers). This naturally concentrates the U.S. Top 10 around immuno-oncology, metabolic disease (obesity/diabetes), autoimmune biologics, and a small number of core antiviral/chronic therapies.
According to Statista’s “Top-selling medicines in the United States by revenue” (as summarized in the figures you provided), the U.S. Top 10 in 2024 is:
Keytruda ($17.87B), Eliquis ($14.43B), Ozempic ($13.26B), Biktarvy ($10.86B), Skyrizi ($10.09B), Dupixent ($9.94B), Mounjaro ($8.95B), Humira ($7.14B), Stelara ($6.72B), and Darzalex ($6.59B).
This list makes the underlying U.S. structure very clear:
- large chronic and immune-mediated populations with sustained prescribing,
- high-priced oncology products with expansion room across indications, and
- strong insurance coverage that can support high-cost therapies.
Keytruda is a textbook example of “premium pricing + indication expansion.” Ozempic and Mounjaro show what happens when a massive patient pool combines with long-term use and expanding clinical utility (e.g., obesity and cardiometabolic risk). Autoimmune blockbusters such as Skyrizi, Dupixent, Humira, and Stelara reinforce that continuity of therapy—not one-time uptake—is often the true engine of revenue. Eliquis, in contrast, demonstrates how sheer prescription volume can produce blockbuster-level sales even without being the highest-priced product.
China outpatient (self-pay/pharmacy) Top 10 drug sales in 2025: pharmacies are becoming a prescription market
China must be analyzed by channel. A single Top 10 list can be misleading because inpatient hospital use and outpatient retail demand behave very differently. The outpatient/retail market, especially, has shown a sharper “prescriptionization” trend.
In the 2025 H1 offline pharmacy Top 10, high-ticket legacy categories such as Human Albumin, Ejiao, and Angong Niuhuang Wan remain prominent, while high-value prescription products—such as bevacizumab—also appear among the leaders.
This mix is meaningful for a simple reason: Chinese pharmacies are still supported by consumer-oriented categories (including traditional products), but prescription outflow and growing “treatment outside hospitals” demand are pushing more high-value prescription medicines into retail. In other words, the outpatient Top 10 is no longer just “what people buy in pharmacies,” but increasingly “which prescriptions are leaving the hospital system.”
From a 2026 perspective, this matters even more. As prescriptionization deepens, the pharmacy channel evolves from a simple point of sale into a service channel that includes prescription validation, supply coordination, and payment pathways (insurance vs. self-pay). For pharma companies, this means China strategy increasingly becomes a two-front game: winning in hospitals is no longer sufficient—outpatient channel strategy can become a second battlefield.
China inpatient (hospital procurement) top 10 drug sales: how to read the “hospital structure” with data
Inpatient hospital sales are far more sensitive to clinical pathways (treatment protocols), inpatient workflow, seasonality and outbreaks, and procurement/price policy than to traditional brand marketing. Hospitals are driven by “institutionalized demand.” Even under price pressure, products that are difficult to substitute or used at high volumes within established care pathways can still generate very large revenue. Conversely, even innovative therapies can be quickly capped if reimbursement, procurement, or pathway entry is constrained.
Looking ahead to 2026, China’s inpatient bestseller structure is still likely to be determined inside a triangle of policy (pricing/procurement), clinical pathways, and volume. That means success in the inpatient channel requires more than a strong product; it requires deliberate market access design and a price–volume strategy that fits procurement realities.
Korea 2025 Top 10 drug sales: revenue follows prescribing penetration, not sticker price
Korea becomes especially clear when viewed through outpatient prescription metrics. Using UBIST-based outpatient prescription sales (2025 H1), the Top 10 includes Rosuzet, K-Cab, Tagrisso, Lipitor, Gliatamin, Plavix, Atorva, Eliquis, Chong Kun Dang Gliatilin, and Livalojet.
The key insight is straightforward: Korea’s Top 10 tends to reward drugs that are widely and consistently prescribed over long periods, not simply those with the highest unit prices. Chronic disease products like Rosuzet, Lipitor, and Eliquis accumulate stable revenue through large patient bases and long duration. K-Cab illustrates what happens when a product secures a “standard-of-care” position in a high-frequency therapeutic area. When a specialty drug such as Tagrisso appears in the Top 10, it usually indicates a convergence of indication scope, guideline positioning, and reimbursement access—conditions that make prescribing “stick.”
In 2026, outpatient penetration is likely to remain the core rule in Korea. As a result, long-horizon pathway building (guidelines, clinical evidence, and reimbursement/patient access design) tends to matter far more than short-term promotional intensity.
Why the U.S., China, and Korea Top 10 lists look so different
At first glance, it may seem like each country simply “prefers different medicines.” A more accurate interpretation is that Top 10 lists diverge because market structures diverge.
First: payer mix and who funds therapy.
The U.S. has strong insurance-driven spending power, which allows high-priced specialty drugs to scale in large indications with long duration—supporting sustained dominance of oncology, metabolic, and autoimmune blockbusters. China’s inpatient channel is shaped more heavily by procurement and price controls; sales can swing significantly based on policy, reimbursement, and inpatient pathway dynamics. Korea’s reimbursement and prescribing environment is highly systematized, making prescribing penetration a stronger determinant of rank than standalone unit price.
Second: channel structure (inpatient vs. outpatient).
China is effectively two different markets: inpatient hospital procurement and outpatient retail. As outpatient pharmacies become more prescription-driven, more high-value medicines can move outside hospitals—reshaping the outpatient Top 10. Korea’s outpatient prescribing metrics naturally elevate chronic disease therapies. In the U.S., even with multiple channels, the “large indication + long duration + coverage” formula still dominates revenue outcomes.
Third: price controls and competitive substitution (including generics and biosimilars).
The stronger the price control environment, the more Top 10 lists tilt toward high-volume products with low substitutability inside clinical pathways. In markets with greater pricing flexibility and payment capacity, high-priced specialty drugs can dominate cash flow for longer. These structural differences explain the “shape” of the 2025 Top 10 lists.
2026 outlook & conclusion: will the “rules” behind 2025 Top 10 continue?
The most useful 2026 question is not “Which drug will be #1?” but “Which market rules will keep working?” Based on the 2025 (and 2025 H1) signals, three directional expectations stand out.
1) In mature markets led by the U.S., GLP-1 (and broader metabolic), autoimmune, and oncology blockbusters are likely to remain the core of Top 10 revenue.
As the U.S. Top 10 demonstrates, when large indications, long treatment duration, and payment capacity align, revenue tends to stay anchored at the top. The sharper competition in 2026 is likely to come less from entirely new launches and more from how existing blockbusters expand—through indication growth, patient population expansion, and coverage/access design.
2) In China, outpatient “prescriptionization” is likely to strengthen further.
The presence of high-value prescription medicines among pharmacy leaders already signals that “treatment outside hospitals” is becoming a real market at scale. China strategy therefore becomes more than hospital entry; it increasingly requires designing outpatient prescribing pathways and payment structures (self-pay, insurance, channel policy) alongside the inpatient plan. Meanwhile, the inpatient channel will remain sensitive to policy, procurement, and clinical pathways, keeping price–volume tradeoffs and access strategy at the center of 2026 execution.
3) In Korea, outpatient prescription penetration will likely remain the dominant revenue engine.
As chronic disease prescribing becomes standardized, revenue accumulates steadily. Specialty therapies enter the Top 10 when the “anchoring conditions” are met—reimbursement, guideline position, and clinical evidence that stabilizes prescribing. In 2026, the key in Korea is not unit price, but the long-term design of the prescribing pathway.
2025 Top 10 lists are not a popularity contest; they are a portrait of payers, channels, and pricing rules. Those rules are likely to remain the primary drivers of 2026 outcomes. Companies that can translate product value into access, channel fit, and durable prescribing—rather than relying on a single clinical talking point—will be best positioned to win.
If you are considering conducting Clinical Trials in Korea and want expert guidance, use our Quotation Request page to get a tailored proposal. Intoinworld’s team – with over 10 years of CRO experience across Phases I–IV and post-market studies – will consult with you to design a strategic plan aligned with MFDS regulations and your project goals.
